Online pharmacy joins blockchain platform for tracing prescriptions

Online pharmacy, My Net Doctor, has signed up to implement the framework blockchain solution developed by Nottingham’s MediConnect for tracing prescriptions.

As a fast-growing online pharmacy, My Net Doctor currently has a userbase of over 10,000, issues approximately 1,000 prescriptions a month and registers around 80 new patients to its website every day.

It joins UK Meds, another online pharmacy partner currently being integrated into the Proof-of-Concept (“PoC”) platform, to extend the reach of MediConnect to over 210,000 patients.

My Net Doctor will now also be integrated into the MediConnect PoC platform ahead of the launch of a pilot scheme in 2020 with up to 10 online pharmacies in total.

As online pharmacies face heightened scrutiny around the over-prescription of medication, MediConnect’s blockchain platform has been designed to trace medication all the way through the supply chain from the point at which it is manufactured to its prescription by medical professionals and purchase by patients.

MediConnect’s private, permissioned distributed ledger will store confidential customer prescription data and provenance data for medicines, which will prevent the misuse and overprescribing of prescription drugs, whilst a public blockchain will be used to transact value using MEDI tokens.

Genevieve Boateng, Director of My Net Doctor, said: “As an online pharmacy, we understand the importance of protecting our patients’ safety and ensuring they are prescribed the correct medication in the right amount.

“We have been extremely impressed with demonstrations of MediConnect’s blockchain solution and look forward to working with them to improve the security and transparency of our processes.”

Dexter Blackstock, CEO of MediConnect, added: “The addition of My Net Doctor to the MediConnect platform is another significant endorsement from the pharmaceutical world for our blockchain solution.”

He added: “We have now started to onboard online pharmacies onto our Proof-of-Concept platform and continue to make great progress ahead of our pilot next year.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Tonix & Southern Research expand COVID-19 vaccine collaboration to include T cell study

New York biopharma, Tonix Pharmaceuticals, has expanded its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2...

Related news

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...